Date: 01/06/2020
HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020. She takes the place of John Hertia who retired from this role on December 31, 2019. Ms. Grantham Wright will be responsible for providing global leadership and management of the overall strategy and business direction for the company’s Clinical Diagnostics Group global operations.
“We are pleased to have Dara join Bio-Rad and believe she will make an excellent addition to our team,” said Andrew Last, Bio-Rad Executive Vice President and Chief Operating Officer. “Dara brings a wealth of experience, business acumen, and a proven track record of success that make her the ideal person to lead our Clinical Diagnostics Group. We would also like to thank John for his many years of valuable contributions to the growth and success of Bio-Rad, and we wish him the best in his retirement,” Dr. Last said.
Ms. Grantham Wright most recently was Vice President & General Manager, Biosciences Division, Life Science Solutions Group, Protein & Cell Analysis, Thermo Fisher Scientific, the company’s largest business unit. Prior to Thermo Fisher Scientific, she was Senior Vice President & General Manager, eBioscience Business Unit at Affymetrix.
Dara has also served with Boreal Genomics as Chief Commercial Officer and with Affymetrix as Global Vice President of Strategic Marketing & Clinical Applications. Prior to Affymetrix, she spent over 10 years in marketing roles at BD Biosciences.
Ms. Grantham Wright holds a Master’s Degree in Business Administration from San Diego State University and a Bachelor of Arts in Biology and Spanish.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding the expected contributions and benefits of the new officer. We have based these statements on the information now known to us. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.
Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com